Deals Shaping the Medical Industry, August 2017
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.
You may also be interested in...
Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can
Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.
Stryker Expands ENT Breadth With $600m-Plus Deal
The orthopedic giant is acquiring Entellus Medical for $24.00 per share, adding to its ear, nose and throat device portfolio with Entellus platforms including XprESS multi-sinus dilation system and the Latera absorbable nasal implant.
Deals In Depth: December 2021
Eight $1bn+ alliances were penned in December. Topping the list was a potential $12.4bn deal between Recursion and Roche (and its Genentech subsidiary) involving the identification and development of small-molecule programs in a gastrointestinal cancer indication and in key areas of neuroscience. Recursion is responsible for creating a certain number of PhenoMaps, which are massive relational databases of biological and chemical perturbation phenotypes. For each of the PhenoMaps requested by Roche, Recursion may be subject to an initiation fee up to $250m for sixteen accepted PhenoMaps. Recursion will receive an up-front payment of $150m and is eligible for additional performance-based research milestones. Roche and Genentech have the option to obtain an exclusive license to initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300m in development, commercialization, and sales milestones for Recursion.